AUTHOR INDEX

(P = proceedings; S = supplement)

AARONS, L. *see* DAVIS, J.D.
ABRAMS, S.M.L. *see* LLEDO, P.
AHSAN, C.H. *see* RENWICK, A.G.
AJAYI, A.A., RAJI, M.A., AKINTAMIDE, A.O. & BABALOLA, R.O. The cardiovascular effects of the concurrent administration of ACE inhibitor, calcium antagonist or α_1-adrenoceptor blocker in healthy Africans, 176P
AKINTAMIDE, A.O. *see* AJAYI, A.A.
AKL, E.-S.K. *see* ALLEN, S.P.
AL-LANQAWI, Y., MORELAND, T.A., MCEWEN, J., HALLIDAY, F., DURNIN, C.J. & STEVENSON, I.H. Ethanol kinetics: extent of error in back extrapolation procedures, 316
ALLEN, A., BULLMAN, S., DAVY, M., PIERCE, D.M., UPWARD, J. & YEE, K.F. The pharmacokinetics of granisetron, a novel, highly selective 5-HT_3-receptor antagonist in healthy male and female volunteers, 175P
ALLEN, G.D. *see* DENWORTHY, D.
ALLEN, S.P., CHESTER, A.H., PIPER, P.J., SAMPSON, A.P., AKL, E.-S.K. & YACOUB, M.H. Effects of leukotrienes C_4 and D_4 on human isolated saphenous veins, 409
ALLGEN, J. *see* OLSSON, G.
ALPS, B.J. Drugs acting on calcium channels: potential treatment for ischaemic stroke, 199
ANDERSON, J. *see* ELEY, J.G.
ANDERSSON, T. *see* UNGE, P.
ANNANE, D. *see* DEMOLIS, P.
ANTIA, I.J., DORKINS, C.E., WOOD, A.J. & ARONSON, J.K. Increase in Na^+/K^+ pump numbers *in vivo* in healthy volunteers taking oral lithium carbonate and further upregulation in response to lithium *in vitro*, 535
ARNOLD, J.M.O., LUI, A.S. & THOMPSON, M. Does rapid development of tachyphylaxis to angiotensin II occur with local venous infusion?, 443P
ARONSON, J.K. *see* ANTIA, I.J.
ARTESI, C. *see* PISANI, F.
ASHFORTH, E. *see* HAYES, K.
AVIRAMI, M. *see* LEVY, Y.
AWADZI, K. & GILLES, H.M. Diethylcarbamazepine in the treatment of patients with onchocerciasis, 281
AYESHI, R. *see* ZHANG, A.Q.

BABALOLA, R.O. *see* AJAYI, A.A.
BACK, D. *see* BARRY, M.
BACK, D.J. *see* HOWE, J.L.
BACK, D.J. *see* WARD, S.
BAGHERI, H., SCHMITT, L., BERLAN, M. & MONTASTRUC, J.L. Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants, 555
BAILEY, R.R. *see* PRATT, M.C.
BAIRD, D.K. *see* HE, G.-W.
BANNWARTH, B., NETTER, P., LAPICQUE, F., GILLET, P., PERE, P., BOCCARD, E., ROYER, R.J. & GAUCHER, A. Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol, 79
BARDIN, P.G. *see* JOHNSTON, S.L.
BARHAM, H.M., LENNARD, M.S., TUCKER, G.T. & WOODS, H.F. Quinine, quinidine inhibition of metoprolol metabolism in DA and Wistar rat liver microsomes, 161P
BARKER, P. *see* MUSHAMBI, M.C.
BARNES, P.J. *see* STONE, R.A.
BARRY, M., HOWE, J., BACK, D., BRECKENRIDGE, A., BRETTLE, R., MITCHELL, R., BEECHING, N. & NYE, F. Effect of non-steroidal anti-inflammatory drugs on zidovudine pharmacokinetics, 446P
BASSENGE, E. Clinical relevance of endothelium-derived relaxing factor (EDRF), 37S
BATEMAN, D.N. Clinical pharmacology—the European challenge, 375
BATEMAN, D.N. *see* CAMPBELL, M.
BATEMAN, D.N. *see* KENNEDY, J.G.
BATEMAN, D.N., RAWLINS, M.D. & SANDERS, G.L.S. Attitudes to adverse drug reaction reporting in the Northern region, 158P
BATEMAN, D.N., SANDERS, G.L.S. & RAWLINS, M.D. Attitudes to advese drug reaction reporting in the Northern region, 421
BAUER, K.G., BRUNNER-FERBER, F., DISTLERATH, L.M., LIPPA, E.A., BINKOWITZ, B., TILL, P. & KAIK, G.A. Assessment of bronchial effects following topical administration of butylamino-phenoxy-propanol-acetate, an oculoselective β-adrenoceptor blocker in asthma, 122
BEARN, J., LIGHTMAN, S. & CHECKLEY, S.A. Central oestrogen receptor function in menopausal women, 462P
BECHARD, S. *see* YOGENDRAN, L.
BEECHING, N. *see* BARRY, M.
BEERAHEE, M. *see* DENWORTHY, D.
BELCH, J.J.F. *see* BRIDGES, A.B.
BELLINGAN, G.J., DIXON, C.M.S. & IND, P.W. Inhibition of inhaled metabisulphite-induced bronchoconstriction by inhaled frusemide and ipratropium bromide, 71
BELZ, G.G. *see* DE MAY, C.
BENNETT, C. *see* SHEPHERD, A.M.M.
BENNETT, P.N. *see* NOTARIANNI, L.J.
BERDEAUX, A. *see* DURANTEAU, J.
BERLAN, M. *see* BAGHERI, H.
BERLIN, I. *see* DANJOU, P.
BEST, N.G., TRULL, A.K., TAN, K.K.C., HUE, K.L., SPIEGELHALTER, D.J., GORE, S.M. & WALLWORK, J. Blood cyclosporin concentrations and the short-term risk of lung rejection following heart-lung transplantation, 513
BEVAN, E.G., CHEE, L.C. & MCINNES, G.T. Patients' attitudes to participation in clinical trials, 156P
BHARGAVA, G. *see* MACINTYRE, P.D.
BINKOWITZ, B. *see* BAUER, K.G.
BINTEIN, T. *see* CHALLIER, J.C.
BIOLLAZ, J. *see* CHATTON, J.Y.
BIRKETT, D.J. *see* MINERS, J.O.
BIRKETT, D.J. *see* TASSENEEYAKUL, W.
BLAIN, P.G. *see* MCCRACKEN, N.
BLANKSON, E.A. *see* DANIELS, L.
BLOM, H. *see* UNGE, P.
BOCCARD, E. *see* BANNWARTH, B.
BOCHNER, F. *see* MILNE, R.W.
BOWES, S.G. *see* KIROLLOS, C.
BOWHAY, A. *see* CHOONARA, I.
BOYES, R.N. Bioequivalence of inhaled medications, 309
BRADBURY, H., BURNS, E., STANNERS, A., TRAVERS, A.F., MCALEER, S.C. & CHRYSTYN, H. The clearance of warfarin and its enantiomers in the elderly, 154P
BRADLEY, J.P. *see* SCHNEIDER, J.J.
BREATHNACH, A. *see* BUGGY, D.
BRECKENRIDGE, A. *see* BARRY, M.
BRECKENRIDGE, A.M. *see* COLEMAN, M.D.
BRECKENRIDGE, A.M. *see* NG, H.W.K.
BRECKENRIDGE, A.M. *see* PIRMOHAMED, M.
BRENNAN, B. *see* DAVIS, J.D.
BRENNAN, G. *see* DUFFIN, D.
BRETTLE, R. *see* BARRY, M.
BRIDGES, A.B., PRINGLE, T.H., MCNEILL, G.P., TAVENDALE, R. & BELCH, J.J.F. β-adrenoceptor antagonists enhance white blood

cell aggregation in patients with ischaemic heart disease, 272
BROCKMÖLLER, J., KOCHLING, J., WEBER, W., LOOBY, M., ROOTS, I. & NEUMAYER, H.-H. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients, 499
BRODERICK, W.M. *see* EDWARDS, C.
BROOK, J.G. *see* LEVY, Y.
BRØSEN, K. *see* SKJELBO, E.
BROWN, A.M. *see* SCHNEIDER, J.J.
BRUCE-JONES, P. *see* FOWLES, S.E.
BRUNNER-FERBER, F. *see* BAUER, K.G.
BUGGY, D., BREATHNACH, A., KEOGH, B., COOK, T. & FEELY, J. Treatment-related differences in lipoprotein(a) in patients with end stage kidney disease, 462P
BULLMAN, J.N. *see* DENWORTHY, D.
BULLMAN, S. *see* ALLEN, A.
BULLOCK, R. Introducing NMDA antagonists into clinical practice: why head injury trials? 396
BURNS, E. *see* BRADBURY, H.
BUTZER, R. *see* DE MEY, C.

CALDWELL, J. *see* HOTCHKISS, S.A.M.
CALDWELL, J. *see* NASSERI-SINA, P.
CAMPBELL, M., BATEMAN, D.N. & SMITH, J.M. Analysis of GP prescribing in the northern region using PACT data, 184P
CAMPBELL COWAN, J. Avoiding nitrate tolerance, 96
CARBERRY, P.A. *see* SHEPHERD, A.M.M.
CARPENTER, J.R. *see* FOSTER, R.W.
CASTAGNA, F. *see* FERRARA, S.D.
CAVENAGH, J.D. *see* SCHNEIDER, J.J.
CHALLENOR, V.F. *see* RENWICK, A.G.
CHALLIER, J.C., REY, E., BINTEIN, T. & OLIVE, G. Passage of S(+)- and R(−)-γ-vinyl-GABA across the human isolated perfused placenta, 139
CHALMERS, D, WHITEHEAD, A. & LAWSON, D.H. Postmarketing surveillance of captopril for hypertension, 215
CHALON, S. *see* DEMOLIS, P.
CHAMBERS, I.R. *see* KANE, P.J.
CHAN, J.C.N., TOMLINSON, B., CRITCHLEY, J.A.J.H., COCKRAM, C.S. & WALDEN, R.J. Metabolic and haemodynamic effects of metformin and glibenclamide in normotensive patients with non-insulin-dependent diabetes mellitus, 442P
CHAN, R., HEMERYCK, L., STINSON, J., CLANCY, L. & FEELY, J. Comparison of oral *vs* intravenous antibiotics for community-acquired lower respiratory tract infection in a general hospital: preliminary results, 447P
CHAN, R., RYAN, M., MORIATY, S., SABRA, K. & FEELY, J. Delay in the administration of intravenous antibiotics and the effect of a centralised reconstitution of intravenous antibiotics service, 458P
CHANDRASEKAR, P.H. *see* TOUCHETTE, M.A.
CHANIWANA, S.K. *see* SIMOOYA, O.O.
CHARLETT, A. *see* KIROLLOS, C.
CHATTON, J.Y., MUNAFO, A., CHAVE, J.P., STEINHAUSLIN, F., ROCH-RAMEL, F., GLAUSER, M.P. & BIOLLAZ, J. Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide, 551
CHAVE, J.P. *see* CHATTON, J.Y.
CHECKLEY, S.A. *see* BEARN, J.
CHEE, L.C. *see* BEVAN, E.G.
CHENERY, R. *see* HAYES, K.
CHENERY, R.J. *see* HARRELL, A.W.
CHESTER, A.H. *see* ALLEN, S.P.
CHING, M.S. *see* ELLIS, S.W.
CHOONARA, I., LAWRENCE, A., MICHALKIEWICZ, A., BOWHAY, A. & RATCLIFFE, J. Morphine metabolism in neonates and infants, 434
CHRYSTYN, H. *see* BRADBURY, H.
CHRYSTYN, H. *see* HINDLE, M.
CHRYSTYN, H. *see* MCALEER, S.D.
CHRYSTYN, H. *see* NWAFOR, S.
CHUA, A., DINAN, T.G. & KEELING, P.W.N. Abnormal cholecystokinin response and hypersensitive central 5-hydroxy-tryptaminergic receptors in non-ulcer dyspepsia, 464P
CHUA, A., KEELING, P.W.N. & DINAN, T.G. Central α_2-adrenoceptors functioning in functional bowel disorder, 448P
CLANCY, L. *see* CHAN, R.
CLARE, C. *see* MILLSON, D.S.
CLARKE, S.E. *see* HARRELL, A.W.
COCKRAM, C.S. *see* CHAN, J.C.N.
COGAN, U. *see* LEVY, Y.
COLEMAN, D. *see* GALLAGHER, P.
COLEMAN, M.D., RHODES, L.E., SCOTT, A.K., VERBOV, J.L., FRIEDMANN, P.S., BRECKENRIDGE, A.M. & PARK, B.K. The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients, 244
CONNELL, J.M.C., JARDINE, A.G. & NORTHRIDGE, D.B. Therapeutic use of atrial natriuretic factor, 102
COOK, A.J., SAMPSON, A.P., GREEN, C.P., SPENCER, D.A., PIPER, P.J. & PRICE, J.F. Leukotrienes in infants with acute viral bronchiolitis, 155P
COOK, T. *see* BUGGY, D.
COSTIGAN, M.G., GILCHRIST, T.L. & LINDUP, W.E. Inhibitors of plasma protein binding and the renal secretion of organic acids, 175P
CREAN, P.A. *see* SHEAHAN, R.G.
CREWE, H.K., LENNARD, M.S., TUCKER, G.T., WOODS, F.R. & HADDOCK, R.E. The effect of selective serotonin re-uptake inhibition on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes, 262
CRITCHLEY, J.A.J.H. *see* CHAN, J.C.N.
CROME, P. *see* FOWLES, S.E.
CROME, P., WIJAYAWARDHANA, P., MULLER, F.O., VAN DYK, M., HUNDT, H.K.L., LUUS, H.G., GROENEWOUD, G. & LEIGHTON, G. A study to compare the single dose and steady-state pharmacokinetic profile and cardiovascular effects of nifedipine LA 60 mg in elderly and young volunteers, 178P
CROTTY, B. & JEWELL, D.P. Drug therapy of ulcerative colitis, 189
CUSSANS, N.J. Hurdles to oral delivery of an atriopeptidase inhibitor (candoxatril) via a prodrug approach, 171P

DAMANI, L.A. *see* NNANE, J.P.
DANIELS, L., BLANKSON, E.A., HENDERSON, C.J., HARRIS, A.H., WOLF, C.R., LENNARD, M.S. & TUCKER, G.T. Delineation of human cytochromes P450 involved in the metabolism of tamoxifen, 153P
DANIELS, R. *see* RENWICK, A.G.
DANIELS, S. *see* FAIRLESS, A.J.
DANJOU, P., MOLINIER, P., BERLIN, I., PATAT, A., ROSENZWEIG, P. & MORSELLI, P.L. Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects, 328
DAVIS, J.D., BRENNAN, B., AARONS, L. & HOUSTON, J.B. Steady state effects of ciprofloxacin and enoxacin on theophylline pharmacokinetics, 169P
DAVY, M. *see* ALLEN, A.
DAWSON, A. *see* HOSIE, J.
DE MARIE, S. *see* MATTIE, H.
DE MEY, C., MATTHEWS, J., BUTZER, R., SCHROETER, V. & BELZ, G.G. Agreement and reproducibility of the estimates of cardiovascular function by impedance cardiography and M-mode echocardiography in healthy subjects, 88

DE SCHEPPER, P.J. *see* VAN HECKEN, A.M.
DEMOLIS, P., CHALON, S., ANNANE, D., DUHAZE, P. & GIUDICELLI, J.F. Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers, 224
DENWORTHY, D., FILER, C.W., SMITH, B., TOMLINSON, P.W., BEERAHEE, M., BULLMAN, J.N., ALLEN, G.D., NASH, M. & TASKER, T.C. The disposition and pharmacokinetics of [^{14}C]-levcromakalim in man, 449P
DEPRE, M. *see* VAN HECKEN, A.M.
DEVLIN, A.M. Development of an analytical method for the specific assay of angiotensin II in human plasma by the combination of h.p.l.c. with r.i.a., 457P
DHADYALLA, A.S., LENNARD, M.S. & TUCKER, G.T. Moclobemide-kinetics and metabolisms in the rat isolated perfused liver, 162P
DINAN, T.G. *see* CHUA, A.
DISTLERATH, L.M. *see* BAUER, K.G.
DIXON, C.M.S. *see* BELLINGAN, G.J.
DOBBS, R.J. *see* KIROLLOS, C.
DOBBS, S.M. *see* KIROLLOS, C.
DOECKE, C.J. *see* TASSENEEYAKUL, W.
DOLBEN, J. *see* ROBLING, M.R.
DONATELLI, P. *see* PACIFICI, G.M.
DORKINS, C.E. *see* ANTIA, I.J.
DOUGLAS, J.T. *see* GEMMILL, J.D.
DREWE, J., MEIER, R., VONDERSCHER, J., KISS, D., POSANSKI, U., KISSEL, T. & GYR, K. Enhancement of the oral absorption of cyclosporin in man, 60
DRUCKER, R.F. *see* WRIGHT, D.M.
DUFFIN, D., LEAHEY, W., BRENNAN, G. & JOHNSTON, G.D. The effects of indomethacin on the antihypertensive responses to enalapril and lisinopril, 456P
DUHAZE, P. *see* DEMOLIS, P.
DUNN, F.G. *see* GEMMILL, J.D.
DUPONT, A.G. *see* VERCRUYSSE, I.
DUPONT, A.G. *see* WAGEMANS, I.
DURANTEAU, J., PUSSARD, E., EDOUARD, A., SAMII, K., BERDEAUX, A. & GIUDICELLI, J.F. Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers, 207
DURHAM, J.M. *see* VAN HECKEN, A.M.
DURNIN, C.J. *see* AL-LANQAWI, Y.

EAGLING, V. *see* HOWE, J.L.
EDOUARD, A. *see* DURANTEAU, J.
EDWARDS, C., BRODERICK, W.M., PEEL, D., HANDLEY, G. & PURVES, I.N. The use of laboratory tests in general practice as markers for medical audit and indicators of iatrogenic disease, 183P
EDWARDS, D.J. *see* TOUCHETTE, M.A.
ELEY, J.G., WHATELEY, T.L., KERR, D.J., MCARDLE, C.S. & ANDERSON, J. Incorporation of mitomycin-c (MMC) into ethylcellulose microcapsules: evaluation of a phase I study in patients with liver metastases, 186P
ELLIOTT, H.L. *see* SCHAFERS, R.F.
ELLIS, S.W., CHING, M.S., WATSON, P., LENNARD, M.S., TUCKER, G.T. & WOODS, H.F. Catalytic activity of human debrisoquine 4-hydroxylase (CYP2D6) heterologously expressed in *Saccharomyces cerevisiae*, 152P
ERHARDT, L. & PARKER, J.O. Preface, 1S
ERHARDT, L. Nitrates today and tomorrow: introduction, 3S
EVANS, S.M.H. *see* PAXTON, J.W.

FAIRLESS, A.J., PRATT, S.K., PUE, M.A., FOWLES, S.E., WOLF, D., DANIELS, S. & PRINCE, W.T. An investigation into the potential interaction between theophylline and oral famciclovir in healthy male volunteers, 171P
FARMER, K.C. *see* LLEDO, P.
FARMER, K.C. *see* NOTARIANNI, L.J.
FARWELL, J. *see* GOROG, D.
FARWELL, J. *see* SEERHA, R.
FAZIO, A. *see* PISANI, F.
FEARNLEY, D. *see* SEERHA, R.
FEELY, J. *see* BUGGY, D.
FEELY, J. *see* CHAN, R.
FEELY, J. *see* HALL, M.
FEELY, J. *see* SHARMA, S.C.
FEELY, J. *see* STINSON, J.
FEELY, M. *see* MCALEER, S.D.
FEELY, M. *see* NWAFOR, S.
FEELY, J. *see* CHAN, R.
FELL, G.L. *see* LEIGH, T.J.
FERNER, R.E. & SCOTT, D.K. The nature and content of advertisements for medicines, 158P
FERNER, R.E. Letter to the Editors. 'Acceptable' risk of drug treatment, 144
FERRARA, S.D., ZOTTI, S., TEDESCHI, L., FRISON, G., CASTAGNA, F., GALLIMBERTI, L., GESSA, G.L. & PALATINI, P. Pharmacokinetics of γ-hydroxy-butyric acid in alcohol dependent patients after single and repeated oral doses, 231
FILER, C.W. *see* DENWORTHY, D.
FOLEY, J.B. *see* SHEAHAN, R.G.
FOONDON, A.S. *see* MCALEER, S.D.
FOSTER, R.W., RAKSHI, K., CARPENTER, J.R. & SMALL, R.C. Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test, 527
FOWLER, P.A. *see* VAN HECKEN, A.M.
FOWLER, P.A., SWEETLAND, J., LOBO, D. & THOMAS, M. The effect of ondansetron on the flare response produced by intradermal 5-HT, 181P
FOWLES, S.E. *see* FAIRLESS, A.J.
FOWLES, S.E., PIERCE, D., LAROCHE, J., PRATT, S.K., PRINCE, W.T., THOMAS, D. & WOODWARD, A. An investigation into the potential interaction between allopurinol and oral famciclovir in non-patient volunteers, 449P
FOWLES, S.E., PUE, M.A., PIERCE, D., PRATT, S.K., CROME, P., PRINCE, W.T. & BRUCE-JONES, P. Pharmacokinetics of penciclovir in healthy elderly subjects following a single oral administration of 750 mg famciclovir, 450P
FREESTONE, S. *see* LI KAM WA, T.C.
FRIEDMANN, P.S. *see* COLEMAN, M.D.
FRISON, G. *see* FERRARA, S.D.
FULLER, R.W. *see* STONE, R.A.
FULLER, R.W. *see* THOMAS, V.E.
FUNG, H.-L. Do nitrates differ? 5S

GALLAGHER, P., HENMAN, M., RUSSELL, R.J., COLEMAN, D. & SHANLEY, D.B. Azole resistance in *Candida albicans*: laboratory and clinical findings, 465P
GALLIMBERTI, L. *see* FERRARA, S.D.
GARDNER, C.H. *see* HOUSTON, A.C.
GARDNER, I.B., WALKER, D., SMITH, D.A., LENNARD, M.S. & TUCKER, G.T. Delineation of the uptake and biliary secretion of indocyanine in the rat isolated perfused liver, 162P
GARNETT, A. *see* HOTCHKISS, S.A.M.
GAUCHER, A. *see* BANNWARTH, B.
GEARTY, G.F. *see* SHEAHAN, R.G.
GELBOIN, H.V. *see* HAKKOLA, J.
GEMMILL, J.D. *see* MACINTYRE, P.D.
GEMMILL, J.D., HOGG, K.J., DUNN, F.G., RAE, A.P. & HILLIS, W.S. Prediction of streptokinase resistance titres (SKRT) at 12 months following streptokinase-containing thrombolytic agents, 455P
GEMMILL, J.D., HOGG, K.J., MACINTYRE, P.D., LOWE, G.D.O., DOUGLAS, J.T., RAE, A.P., DUNN, F.G. & HILLIS, W.S. Unsuccessful thrombolysis following streptokinase-containing agents in acute myocardial infarction is related to

pretreatment fibrinogen levels, 455P
GEORGE, C.F. *see* RENWICK, A.G.
GERDIN, E. & RANE, A. *N*-demethylation of ethylmorphine in pregnant and non-pregnant women and in men: an evaluation of the effects of sex steroids, 250
GESSA, G.L. *see* FERRARA, S.D.
GILCHRIST, T.L. *see* COSTIGAN, M.G.
GILES, H. *see* GRAY, S.J.
GILLES, H.M. *see* AWADZI, K.
GILLET, P. *see* BANNWARTH, B.
GIUDICELLI, J.F. *see* DEMOLIS, P.
GIUDICELLI, J.F. *see* DURANTEAU, J.
GIULIANI, L. *see* PACIFICI, G.M.
GLAUSER, M.P. *see* CHATTON, J.Y.
GODTFREDSEN, S. *see* ROBLING, M.R.
GOLDBERG, P. *see* THOM, S. MCG.
GOODEVE, A.C. *see* HIGGINS, K.S.
GORE, S.M. *see* BEST, N.G.
GOROG, D., ROBERTSHAW, H., FARWELL, J., TABAQCHALI, S. & TURNER, P. Intravenous anti-infective drug prescribing in hospitals of a district health authority, 459P
GRAY, S.J., GILES, H. & POSNER, J. The effect of a prostaglandin DP-receptor partial agonist (192C86) on platelet aggregation and the cardiovascular system in healthy volunteers, 344
GREEN, C.P. *see* COOK, A.J.
GRIGGS, W.M. *see* MILNE, R.W.
GROENEWOUD, G. *see* CROME, P.
GROSSET, D.G. Clinical, radiological, and functional evaluation following acute stroke, 477
GUY, S., JEFFERS, L.A., HARRIS, C.M. & RIDDELL, J.G. The selectivity of the partial agonist activity of celiprolol, 179P
GUY, S., THAM, T.C.K., SILKE, B. & RIDDELL, J.G. The effects of α- and β-adrenoceptor antagonists on the heart rate, cardiac output, blood pressure, forearm blood flow and finger tremor responses to dobutamine infusion, 179P
GYR, K. *see* DREWE, J.

HADDOCK, R.E. *see* CREWE, H.K.
HAKKOLA, J., MÄENPÄÄ, J., MAYER, R.T., PARK, S.S., GELBOIN, H.V. & PELKONEN, O. 7-alkoxyquinolone *O*-dealkylation by microsomes from human liver and placenta, 415
HALL, M., MCCORMACK, P.M. & FEELY, J. The ability of doctors and nurses in hospital to recognise commonly prescribed drugs, 460P
HALLIDAY, F. *see* AL-LANQAWI, Y.
HANDLEY, G. *see* EDWARDS, C.
HANKEY, C.R. *see* SUMMERBELL, J.
HARDY, E., RUBIN, P.C. & HORN, E.H. Effects of Sin-L, SNP and M&B22948 on the platelet release reaction in normal pregnancy and pre-eclampsia, 181P
HARRELL, A.W., WHEELER, S.M., PENNICK, M., CLARKE, S.E. & CHENERY, R.J. Lack of inhibitory effect of famciclovir (BRL 42810) and associated metabolites on human P450 3A4 *in vitro*, 164P
HARRIS, A.H. *see* DANIELS, L.
HARRIS, C.M. *see* GUY, S.
HARRISON, A.C., PARK, B.K., O'NEILL, P.M., STORR, R.C. & KITTERINGHAM, N.R. Metabolic defluorination of 5-fluoro-amodiaquine in the rat, 148P
HARRISON, A.J. *see* THOMAS, V.E.
HARRISON, J. *see* JOHNSTON, S.L.
HART, C.A. *see* HOWE, J.L.
HAWKSWORTH, G.M. *see* NEWLANDS, A.J.
HAYES, K., ASHFORTH, E., CHENERY, R. & HOUSTON, J.B. Prediction of phenytoin clearance from hepatocyte data, effect of albumin in hepatocyte incubation media, 168P
HE, G.-W., SHAW, J., YANG, C.-Q., HUGHES, C., THOMSON, D., MCCAUGHAN, B., HENDLE, P.N. & BAIRD, D.K. Inhibitory effects of glyceryl trinitrate on α-adrenoceptor mediated contraction in the human internal mammary artery, 236
HELD, P. Effects of nitrates on mortality in acute myocardial infarction and in heart failure, 25S
HEMERYCK, L. *see* CHAN, R.
HEMERYCK, L. *see* STINSON, J.
HENDERSON, C.J. *see* DANIELS, L.
HENDLE, P.N. *see* HE, G.-W.
HENMAN, M. *see* GALLAGHER, P.
HEWITT, P. *see* HOTCHKISS, S.A.M.
HIGGINS, K. *see* LAKE, S.R.
HIGGINS, K.S., GOODEVE, A.C., YEO, W.W., MORICE, A.H. & PEAKE, I.R. Improved detection of the insertion/deletion polymorphism of the ACE gene and relationship to serum ACE activity in a normotensive UK population, 151P
HILLIS, W.S. *see* GEMMILL, J.D.
HILLIS, W.S. *see* MACINTYRE, P.D.
HILSTED, J. *see* HVIDBERG, A.
HINDLE, M. & CHRYSTYN, H. Determination of the relative bioavailability of salbutamol to the lung following inhalation, 311
HISATOME, I. *see* KINUGAWA, T.
HOGG, K.J. *see* GEMMILL, J.D.
HOGG, K.J. *see* MACINTYRE, P.D.
HOLGATE, S.T. *see* JOHNSTON, S.L.
HORN, E.H. *see* HARDY, E.
HOSIE, J., DAWSON, A., LANGAN, J.J., SCOTT, M. & VERNON, J.P. Tolerability of felodipine and nifedipine in equipotent antihypertensive doses, 454P
HOTCHKISS, S.A. *see* NASSERI-SINA, P.
HOTCHKISS, S.A.M., GARNETT, A., HEWITT, P., MINT, A. & CALDWELL, J. Percutaneous absorption of topically applied chemicals through human skin *in vitro*, 148P
HOUSTON, A.C. & GARDNER, C.H. A survey of volunteer payments in Phase 1 units in the UK: 1988 and 1991, 459P
HOUSTON, A.C. *see* MUIRHEAD, G.J.
HOUSTON, A.C. *see* SHAW, T.M.
HOUSTON, J.B. *see* DAVIS, J.D.
HOUSTON, J.B. *see* HAYES, K.
HOUSTON, J.B. *see* ZOMORODI, K.
HOWE, J. *see* BARRY, M.
HOWE, J.L., BACK, D.J., EAGLING, V. & HART, C.A. Bacterial and hepatic metabolism of zidovudine (AZT) to the toxic catabolite 3′-amino-3′deoxythymidine (AMT), 165P
HOWIE, C.A. *see* SCHAFERS, R.F.
HSEIH, J.Y.-K. *see* YOGENDRAN, L.
HUE, K.L. *see* BEST, N.G.
HUGHES, A.D. *see* THOM, S. MCG.
HUGHES, C. *see* HE, G.-W.
HULTBERG, B. *see* NYBERG, G.F.
HUMPHREY, M.J. *see* WALKER, D.K.
HUNDT, H.K.L. *see* CROME, P.
HUNT, W.B. *see* KIROLLOS, C.
HVIDBERG, A., JØRGENSEN, S. & HILSTED, J. The effect of genetically engineered glucagon on glucose recovery after hypoglycaemia in man, 547

IDSTRÖM, J.-P. *see* UNGE, P.
IND, P.W. *see* BELLINGAN, G.J.

JACKSON, P.R. *see* LAKE, S.R.
JAHNCHEN, E. Plasma profile and haemodynamic tolerance to isosorbide-5-mononitrate in controlled-release form, 15S
JAMES, I.M. *see* YOGENDRAN, L.
JARDINE, A.G. *see* CONNELL, J.M.C.
JEFFERS, L.A. *see* GUY, S.
JEWELL, D.P. *see* CROTTY, B.
JOEL, S. *see* OSBORNE, R.
JOHNSON, M.A. *see* MILLSON, D.S.
JOHNSON, M.A., MCDOWALL, J.E. & KEENE, O.N. The repeatability of change in cardiac function after salmeterol using electrical bioimpedance cardiography, 177P
JOHNSTON, G.D. *see* DUFFIN, D.
JOHNSTON, N.R. *see* LI KAM WA, T.C.
JOHNSTON, S.L., BARDIN, P.G., HARRISON, J., RITTER, W., JOUBERT, J.R. & HOLGATE, S.T. The effects of an oral thromboxane TP receptor antagonist BAY u 3405, on prostaglandin D_2- and histamine-induced bronchoconstriction in

asthma, and relationship to plasma concentrations, 402
JONES, B.C. *see* NEWLANDS, A.J.
JONES, D.L. & SPIERS, J.P. Effect of age on the cellular electrophysiology of cardiomyopathic (CHF 146) and normal (CHF GS) Syrian hamsters, 452P
JONES, D.L. *see* SPIERS, J.P.
JØRGENSEN, S. *see* HVIDBERG, A.
JOUBERT, J.R. *see* JOHNSTON, S.L.

KAIK, G.A. *see* BAUER, K.G.
KANE, P.J., WARD, A., CHAMBERS, I.R., RAWLINS, M.D. & MENDELOW, A.D. Parenteral sodium valproate: a pharmacokinetic study in serum and CSF of patients with severe head injury, 173P
KAPAS, M. *see* RILEY, S.A.
KAY, E. *see* NWAFOR, S.
KEELING, P.W.N. *see* CHUA, A.
KEEN, M. *see* KEY, B.J.
KEENE, O.N. *see* JOHNSON, M.A.
KEENE, O.N. *see* MILLSON, D.S.
KENNA, J.G. Antibodies to halothane-induced liver antigens in sera from patients with halothane hepatitis: evidence for a conformation-dependent antigen, 154P
KENNA, J.G. *see* KITTERINGHAM, N.R.
KENNA, J.G., SCATCHARD, K., VAN PELT, F.N.A.M. & KNIGHT, T.L. Antibodies to halothane-induced liver antigens in sera from patients with halothane hepatitis: evidence for a conformation-dependent antigen, 154P
KENNEDY, J.G. & BATEMAN, D.N. Vasodilator drugs, a negative index of prescribing quality? 461P
KEOGH, B. *see* BUGGY, D.
KERR, D.J. see ELEY, J.G.
KESTELL, P. *see* PAXTON, J.W.
KEY, B.J., KEEN, M. & WILKES, M.P. Reduced responsiveness to nitro-vasodilators following prolonged low dose aspirin administration in man, 453P
KIM, M. *see* RILEY, S.A.
KINUGAWA, T., KITAMURA, H., OGINO, K., NOGUCHI, N., MATSUMOTO, T., HISATOME, I., MIYAKODA, K., KOTAKE, H. & MASHIBA, H. Effect of alacepril on blood pressure and neurohumoral factors at rest and during dynamic exercise in patients with essential hypertension, 366
KIROLLOS, C., O'NEILL, C.J.A., CHARLETT, A., BOWES, S.G., WELLER, C., HUNT, W.B., DOBBS, S.M. & DOBBS, R.J. Measuring the tendency towards clinical parkinsonism: a method for focusing the search for xenobiotic influence in its causation, 185P
KISS, D. *see* DREWE, J.
KISSEL, T. *see* DREWE, J.
KITAMURA, H. *see* KINUGAWA, T.
KITTERINGHAM, N.R. *see* HARRISON, A.C.
KITTERINGHAM, N.R. *see* PARK, B.K.
KITTERINGHAM, N.R., KENNA, J.G., MCCLEAN, C. & PARK, B.K. Detection of autoantibodies directed against human liver microsomal proteins in sera from patients with halothane-associated hepatitis, 166P
KLEIJNEN, J. & KNIPSCHILD, P. *Ginkgo biloba* for cerebral insufficiency, 352
KNIGHT, T.L. *see* KENNA, J.G.
KNIPSCHILD, P. *see* KLEIJNEN, J.
KOCHLING, J. *see* BROCKMÖLLER, J.
KOTAKE, H. *see* KINUGAWA, T.
KUNSMAN, C.M. *see* KUNSMAN, G.W.
KUNSMAN, G.W., MANNO, J.E., MANNO, B.R., KUNSMAN, C.M. & PRZEKOP, M.A. The use of microcomputer-based psychomotor tests for the evaluation of benzodiazepine effects on human peformance, 289

LACEY, L.F. *see* VAN HECKEN, A.M.
LAGERSTRÖM, P.-O. *see* UNGE, P.
LAKE, S.R., YEO, W.W., HIGGINS, K., JACKSON, P.R., MORICE, A.H. & RAMSAY, L.E. Effect of aspirin on the cough reflex of healthy subjects, and relation to salicylate concentration, 182P
LAM, A.M. *see* NYBERG, G.F.
LANGAN, J.J. *see* HOSIE, J.
LAPICQUE, F. *see* BANNWARTH, B.
LAROCHE, J. *see* FOWLES, S.E.
LAWRENCE, A. *see* CHOONARA, I.
LAWSON, D.H. *see* CHALMERS, D.
LEAHEY, W. *see* DUFFIN, D.
LEE, A., RAWLINS, M.D. & SMITH, J.M. A study of expert judgements on adverse drug reaction reports, and comparison with algorithmic methods, 157P
LEE, M.R. *see* LI KAM WA, T.C.
LEES, K.R. *see* MACFADYEN, R.J.
LEES, K.R. Therapeutic interventions in acute stroke, 486
LEIBOWITZ, R. *see* LEVY, Y.
LEIGH, T.J., LINK, C.G.G. & FELL, G.L. Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG, 65
LEIGHTON, G. *see* CROME, P.
LENNARD, M.S. *see* BARHAM, H.M.
LENNARD, M.S. *see* CREWE, H.K.
LENNARD, M.S. *see* DANIELS, L.
LENNARD, M.S. *see* DHADYALLA, A.S.
LENNARD, M.S. *see* ELLIS, S.W.
LENNARD, M.S. *see* GARDNER, I.B.
LEVY, Y., LEIBOWITZ, R., AVIRAMI, M., BROOK, J.G. & COGAN, U. Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolaemia, 427
LEWIS-BARNED, N.J. *see* PRATT, M.C.
LI KAM WA, T.C., FREESTONE, S., SAMSON, R.R., JOHNSTON, N.R. & LEE, M.R. Is γ-L-glutamyl-5-hydroxy-L-tryptophan a renal 5-HT prodrug? A comparison with 5-hydroxy-L-tryptophan in normal man, 149P
LIGHTMAN, S. *see* BEARN, J.
LIN, C. *see* YOGENDRAN, L.
LINDUP, W.E. *see* COSTIGAN, M.G.
LINK, C.G.G. *see* LEIGH, T.J.
LIPPA, E.A. *see* BAUER, K.G.
LIPWORTH, B.J. *see* WHEELDON, N.M.
LIVESEY, J. *see* PRATT, M.C.
LLEDO, P., PATEL, M., FARMER, K.C., NUGENT, K., PHILIPS, R.K.S. & ABRAMS, S.M.L. Debrisoquine hydroxylator status in familial adenomatous polyposis, 164P
LOBO, D. *see* FOWLER, P.A.
LOOBY, M. *see* BROCKMÖLLER, J.
LOWE, G.D.O. *see* GEMMILL, J.D.
LUI, A.S. *see* ARNOLD, J.M.O.
LUSCHER, T.F. Endogenous and exogenous nitrates and their roles in myocardial ischaemia, 29S
LUUS, H.G. *see* CROME, P.
LUZIO, S.D. *see* ROBLING, M.R.

MACFADYEN, R.J., LEES, K.R. & REID, J.L. Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers, 115
MACINTYRE, P.C. *see* GEMMILL, J.D.
MACINTYRE, P.D., BHARGAVA, B., HOGG, K.J., GEMMILL, J.D. & HILLIS, W.S. The effect of i.v. sumatriptan, a selective $5HT_1$-receptor agonist on central haemodynamics and the coronary circulation, 541
MACINTYRE, P.D., GEMMILL, J.D., HOGG, K.J., BHARGAVA, B. & HILLIS, W.S. The effect of subcutaneous sumatriptan (GR43175), a $5HT_1$-receptor agonist, on the systemic, pulmonary and coronary circulations, 454P
MACKLIN, B.S. *see* RENWICK, A.G.
MACRAE, I.M. New models of focal cerebral ischaemia, 302
MADIGAN, M.J. *see* MUIRHEAD, G.J.
MADIGAN, M.J. *see* WILLIAMS, P.E.O.
MÄENPÄÄ, J. *see* HAKKOLA, J.
MANNING, B. & MARTIN, F.

Diagnosis and management of autoimmune chronic active hepatitis patients on immunosuppressive therapy using a novel ELISA-based test system, 464P
MANNO, B.R. *see* KUNSMAN, G.W.
MANNO, J.E. *see* KUNSMAN, G.W.
MARGOLSKEE, D.J. *see* YOGENDRAN, L.
MARTIN, F. *see* MANNING, B.
MASHIBA, H. *see* KINUGAWA, T.
MASSART, D.L. *see* VERCRUYSSE, I.
MATSUMOTO, T. *see* KINUGAWA, T.
MATTHEWS, J. *see* DE MEY, C.
MATTIE, H., DE MARIE, S., SLAGHIUS, G., ROZING, P.M. & VAN STRIJEN, E. Diffusion of cloxacillin into synovial tissue, 275
MAYER, R.T. *see* HAKKOLA, J.
MCADAM, B.F. *see* SHEAHAN, R.G.
MCALEER, S.D. *see* BRADBURY, H.
MCALEER, S.D., FOONDON, A.S., FEELY, M. & CHRYSTYN, H. Steady state serum concentrations of warfarin, R-warfarin, S-warfarin and warfarin alcohol in anticoagulated patients, 172P
MCARDLE, C.S. *see* ELEY, J.G.
MCCAUGHAN, B. *see* HE, G.-W.
MCCLEAN, C. *see* KITTERINGHAM, N.R.
MCCLELLAND, G.R. *see* SHAW, T.M.
MCCORMACK, P.M. *see* HALL, M.
MCCORMACK, P.M.E. *see* STINSON, J.
MCCRACKEN, N., BLAIN, P.G. & WILLIAMS, F.M. Xenobiotic metabolising esterases in human liver and blood, 160P
MCCULLOCH, J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man, 106
MCDEVITT, D.G. *see* WHEELDON, N.M.
MCDOWALL, J.E. *see* JOHNSON, M.A.
MCEWEN, J. *see* AL-LANQAWI, Y.
MCINNES, G.T. *see* BEVAN, E.G.
MCLAUGHLIN, K. *see* YOGENDRAN, L.
MCMANUS, M.E. *see* TASSENEEYAKUL, W.
MCNEILL, G.P. *see* BRIDGES, A.B.
MEECHAN, J.G., WELBURY, R.R. & RAWLINS, M.D. Kalaemotropic effect of adrenaline in local anaesthetic solutions in sedated oral surgery patients, 156P
MEIER, R. *see* DREWE, J.
MELLOR, E. *see* NWAFOR, S.
MENDELOW, A.D. *see* KANE, P.J.
MICHALKIEWICZ, A. *see* CHOONARA, I.
MILAD, M.A. *see* TOUCHETTE, M.A.
MILLSON, D.S., CLARE, C., JOHNSON, M.A., KEENE, O.N. & VENTRESCA, G.P. Effect of acid secretion blockade on the repeatability of gastric emptying measurement using applied potential tomography in healthy subjects, 180P
MILNE, R.W., NATION, R.L., SOMOGYI, A.A., BOCHNER, F. & GRIGGS, W.M. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients, 53
MINERS, J.O. *see* TASSENEEYAKUL, W.
MINERS, J.O., OSBORNE, N.J., TONKIN, A.L. & BIRKETT, D.J. Perturbation of paracetamol urinary metabolic ratios by urine flow rate, 359
MINT, A. *see* HOTCHKISS, S.A.M.
MITCHELL, A.M. *see* MUIRHEAD, G.J.
MITCHELL, A.M. *see* WILLIAMS, P.E.O.
MITCHELL, R. *see* BARRY, M.
MITCHELL, S.C. *see* ZHANG, A.Q.
MIYAKODA, H. *see* KINUGAWA, T.
MOLINIER, P. *see* DANJOU, P.
MONTASTRUC, J.L. *see* BAGHERI, H.
MORELAND, T.A. *see* AL-LANQAWI, Y.
MORIATY, S. *see* CHAN, R.
MORICE, A.H. *see* HIGGINS, K.S.
MORICE, A.H. *see* LAKE, S.R.
MORSELLI, P.L. *see* DANJOU, P.
MOTWANI, J.G. & STRUTHERS, A.D. Captopril augments both basal and frusemide-induced natriuresis in normal man by suppression of circulating angiotensin II, 25
MUIRHEAD, G.J. *see* SHAW, T.M.
MUIRHEAD, G.J. *see* WILLIAMS, P.E.O.
MUIRHEAD, G.J., SHAW, T., WILLIAMS, P.E.O., MADIGAN, M.J., MITCHELL, A.M. & HOUSTON, A.C. Pharmacokinetics of the HIV-proteinase inhibitor, Ro 318959, after single and multiple oral doses in healthy volunteers, 170P
MULLER, F.O. *see* CROME, P.
MUNAFO, A. *see* CHATTON, J.Y.
MUSHAMBI, M.C., TROTTER, T.N., BARKER, P. & ROWBOTHAM, D.J. A comparison of gastric emptying rate after cimetidine and ranitidine measured by applied potential tomography, 278
MUTETWA, S. *see* SIMOOYA, O.O.

NASH, M. *see* DENWORTHY, D.
NASSERI-SINA, P., HOTCHKISS, S.A. & CALDWELL, J. Glycine conjugation in rat and human keratinocytes and rat hepatocytes: comparative studies in isolated and cultured cells, 150P
NATION, R.L. *see* MILNE, R.W.
NEILL, P. *see* SIMOOYA, O.O.
NETTER, P. *see* BANNWARTH, B.
NEUMAYER, H.-H. *see* BROCKMÖLLER, J.
NEWLANDS, A.J., SMITH, D.A., JONES, B.C. & HAWKSWORTH, G.M. Metabolism of non-steroidal anti-inflammatory drugs by cytochrome P450 2C, 152P
NG, H.W.K., WALLEY, T., TSAO, Y. & BRECKENRIDGE, A.M. Interactions of flosequinan and xamoterol in central and peripheral haemodynamics during exercise in normal subjects, 177P
NNANE, J.P. & DAMANI, L.A. Ethyl methyl sulphide: a potential pharmacokinetic probe for monitoring the activity of the flavin-containing monooxygenase *in vivo* in experimental animals, 160P
NOGUCHI, N. *see* KINUGAWA, T.
NORDGREN, A. *see* UNGE, P.
NORTHRIDGE, D.B. *see* CONNELL, J.M.C.
NOTARIANNI, L.J., OLIVER, S., BENNETT, P.N., FARMER, K.C., SPIGELMAN, A. & PHILLIPS, R.K. P4501A2 activity in patients with colorectal carcinoma and familial polyposis (FAP) and their at risk relatives, 153P
NUGENT, K. *see* LLEDO, P.
NWAFOR, S., PULLAR, T., CHRYSTYN, H., KAY, E., MELLOR, E. & FEELY, M. Compliance with drug therapy for congestive cardiac failure, 446P
NYBERG, G.F., LAM, A.M., WESLEY, R.C. & HULTBERG, B. Excretion of urine and *N*-acetyl-glucosaminidase during adenosine- and sodium nitroprusside-induced hypotension in man and pig undergoing isoflurane anaesthesia, 442P
NYE, F. *see* BARRY, M.

O'CONNELL, F. *see* THOMAS, V.E.
O'NEILL, C.J.A. *see* KIROLLOS, C.
O'NEILL, P.M. *see* HARRISON, A.C.
OGINO, K. *see* KINUGAWA, T.
OLIVE, G. *see* HALLIER, J.C.
OLIVER, S. *see* NOTARIANNI, L.J.
OLSSON, G. & ALLGEN, J. Prophylactic nitrate therapy in angina pectoris—is there an optimal treatment regimen?, 19S
OSBORNE, N.J. *see* MINERS, J.O.
OSBORNE, R., THOMPSON, P., JOEL, S., TREW, D., PATEL, N. & SLEVIN, M. The analgesic activity of morphine-6-glucuronide, 130
OTERI, G. *see* PISANI, F.
OWENS, D.R. *see* ROBLING, M.R.

PACIFICI, G.M., DONATELLI, P. & GIULIANI, L. Histamine *N*-methyl transferase: inhibition by drugs, 322
PALATINI, P. *see* FERRARA, S.D.

PARISH, N. *see* SHAW, T.M.
PARK, B.K. *see* COLEMAN, M.D.
PARK, B.K. *see* HARRISON, A.C.
PARK, B.K. *see* KITTERINGHAM, N.R.
PARK, B.K. *see* PIRMOHAMED, M.
PARK, B.K. *see* TINGLE, M.D.
PARK, B.K., PIRMOHAMED, M. & KITTERINGHAM, N.R. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors, 377
PARK, S.S. *see* HAKKOLA, J.
PARKER, J.O. *see* ERHARDT, L.
PARKER, J.O. Update on nitrate tolerance, 11S
PATAT, A. *see* DANJOU, P.
PATEL, M. *see* LLEDO, P.
PATEL, N. *see* OSBORNE, R.
PAXTON, J.W., YOUNG, D., EVANS, S.M.H., KESTELL, P. & ROBERTSON, I.G.C. Tumour profile of *N*-[2-(dimethylamino)-acridine-4-carboxamide (AC) in the mouse, 174P
PEAKE, I.R. *see* HIGGINS, K.S.
PEEL, D. *see* EDWARDS, C.
PELKONEN, O. *see* HAKKOLA, J.
PENNICK, M. *see* HARRELL, A.W.
PERE, P. *see* BANNWARTH, B.
PERUCCA, E. *see* PISANI, F.
PHILIPS, R.K.S. *see* LLEDO, P.
PHILLIPS, R.K. *see* NOTARIANNI, L.J.
PIERCE, D. *see* FOWLES, S.E.
PIERCE, D.M. *see* ALLEN, A.
PIPER, P.J. *see* ALLEN, S.P.
PIPER, P.J. *see* COOK, A.J.
PIRMOHAMED, M. *see* PARK, B.K.
PIRMOHAMED, M., TEMPLETON, E., BRECKENRIDGE, A.M. & PARK, B.K. *In vitro* bioactivation of clozapine to a chemically reactive metabolite by human and mouse liver microsomes, 168P
PISANI, F., FAZIO, A., ARTESI, C., OTERI, G., SPINA, E., TOMSON, T. & PERUCCA, E. Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects, 85
POSANSKI, U. *see* DREW, J.
POSNER, J. *see* GRAY, S.J.
PRATT, M.C., LEWIS-BARNED, N.J., WALKER, R.J., BAILEY, R.R., SHAND, B.I. & LIVESEY, J. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentration in healthy volunteers, 363
PRATT, S.K. *see* FAIRLESS, A.J.
PRATT S.K. *see* FOWLES, S.E.
PRICE, J.F. *see* COOK, A.J.
PRINCE, W.T. *see* FAIRLESS, A.J.
PRINCE, W.T. *see* FOWLES, S.E.
PRINGLE, T.H. *see* BRIDGES, A.B.
PRINGLE, T.H. *see* WHEELDON, N.M.
PRZEKOP, M.A. *see* KUNSMAN, G.W.
PUE, M.A. *see* FAIRLESS, A.J.
PUE, M.A. *see* FOWLES, S.E.
PULLAR, T. Letter to the Editors. 'Acceptable' risk of drug treatment, 144
PULLAR, T. *see* NWAFOR, S.
PURVES, I.N. *see* EDWARDS, C.
PUSARD, E. *see* DURANTEAU, J.

RAE, A.P. *see* GEMMILL, J.D.
RAJI, M.A. *see* AJAYI, A.A.
RAKSHI, K. *see* FOSTER, R.W.
RALSTON, S.H. Medical management of hypercalcaemia, 11
RAMSAY, L.E. *see* LAKE, S.R.
RAMSAY, L.E. *see* TUCKER, G.T.
RANE, A. *see* GERDIN, E.
RATCLIFFE, J. *see* CHOONARA, I.
RAVENSCROFT, P.J. *see* SCHNEIDER, J.J.
RAVIC, M., WARRINGTON, S.J. & TURNER, P. Effect of dobutamine and digoxin on aortic blood velocity estimated with Doppler ultrasound, 451P
RAWLINS, M.D. *see* BATEMAN, D.N.
RAWLINS, M.D. *see* KANE, P.J.
RAWLINS, M.D. *see* LEE, A.
RAWLINS, M.D. *see* MEECHAN, J.G.
RAWLINS, M.D. *see* WYNNE, H.A.
REED, M.D. Letter to the Editors. Odansetron as an antiemetic, 144
REID, J.L. *see* MACFADYEN, R.J.
REID, J.L. *see* SCHAFERS, R.F.
REILLY, C.S. *see* WHALLEY, P.M.
RENWICK, A.G., AHSAN, C.H., CHALLENOR, V.F., DANIELS, R., MACKLIN, B.S., WALLER, D.G. & GEORGE, C.F. The influence of posture on the pharmacokinetics of orally administered nifedipine, 332
REY, E. *see* CHALLIER, J.C.
RHODES, L.E. *see* COLEMAN, M.D.
RIDDELL, J.G. *see* GUY, S.
RILEY, S.A., KIM, M., SUTCLIFFE, R., KAPAS, M., ROWLAND, M. & TURNBERG, L.A. Effects of a non-absorbable osmotic load on drug absorption in healthy volunteers, 40
RILEY, S.A., SUTCLIFFE, F., KIM, M., ROWLAND, M. & TURNBERG, L.A. The influence of gastrointestinal transit on drug absorption in healthy volunteers, 32
RITTER, W. *see* JOHNSTON, S.L.
ROBERTSHAW, H. *see* GOROG, D.
ROBERTSON, I.G.C. *see* PAXTON, J.W.
ROBLING, M.R., DOLBEN, J., LUZIO, S.D., GODTFREDSEN, S. & OWENS, D.R. Single dose-response study of a new oral hypoglycaemic agent in diet-treated patients with non-insulin-dependent diabetes mellitus (NIDDM), 173P
ROCH-RAMEL, F. *see* CHATTON, J.Y.
ROGERS, J.D. *see* YOGENDRAN, L.
ROOTS, I. *see* BROCKMÖLLER, J.
ROSENZWEIG, P. *see* DANJOU, P.
ROWBOTHAM, D.J. *see* MUSHAMBI, M.C.
ROWLAND, M. *see* RILEY, S.A.
ROYER, R.J. *see* BANNWARTH, B.
ROZING, P.M. *see* MATTIE, H.
RUBIN, P.C. *see* HARDY, E.
RUSSELL, R.J. *see* GALLAGHER, P.
RYAN, M. *see* CHAN, R.

SABRA, K. *see* CHAN, R.
SALEH, S. & TURNER, P. Ocular hypotensive effects of medifoxamine, 269
SAMII, K. *see* DURANTEAU, J.
SAMPSON, A.P. *see* ALLEN, S.P.
SAMPSON, A.P. *see* COOK, A.J.
SAMSON, R.R. *see* LI KAM WA, T.C.
SANDERS, G.L.S. *see* BATEMAN, D.N.
SANSOM, L.N. *see* TASSENEEYAKUL, W.
SCATCHARD, K. *see* KENNA, J.G.
SCHAFERS, R.F., ELLIOTT, H.L., HOWIE, C.A. & REID, J.L. A preliminary, clinical pharmacological assessment of L-659,066, a novel α_2-adrenoceptor antagonist, 521
SCHMITT, L. *see* BAGHERI, H.
SCHNEIDER, J.J., RAVENSCROFT, P.J., CAVENAGH, J.D., BROWN, A.M. & BRADLEY, J.P. Plasma morphine-3-glucuronide, morphine-6-glucuronide and morphine concentrations in patients receiving long-term epidural morphine, 431
SCHOLLER, I. *see* SHEPHERD, A.M.M.
SCHOORS, D.F. *see* VERCRUYSSE, I.
SCHOORS, D.F. *see* WAGEMANS, I.
SCHROETER, V. *see* DE MEY, C.
SCIBERRAS, D.G. *see* YOGENDRAN, L.
SCOTT, A.K. *see* COLEMAN, M.D.
SCOTT, D.K. *see* FERNER, R.E.
SCOTT, M. *see* HOSIE, J.
SEERHA, R., FEARNLEY, D., FARWELL, J., TABAQCHALI, S. & TURNER, P. A descriptive survey of anti-infective drug prescribing within four district health authority hospitals, 458P
SEVER, P.S. *see* THOM, S. MCG.
SHAND, B.I. *see* PRATT, M.C.
SHANLEY, D.B. *see* GALLAGHER, P.
SHARMA, S.C. & FEELY, J. Alcohol-related increase in leucocytes and lymphocytes in human subjcts, 460P
SHAW, J. *see* HE, G.-W.
SHAW, T. *see* MUIRHEAD, G.J.
SHAW, T. *see* WILLIAMS, P.E.O.
SHAW, T.M., MUIRHEAD, G.J., PARISH, N., MCCLELLAND, G.R. & HOUSTON, A.C. Tolerability and pharmacokinetics of single oral doses of Ro 31-8959, an HIV proteinase inhibitor, 166P

SHEAHAN, R.G., FOLEY, J.B., MCADAM, B.F., CREAN, P.A., GEARTY, G.F. & WALSH, M.J. Myocardial ischaemia following coronary angioplasty: are nitrates beneficial? 444P
SHEPHERD, A.M.M., CARBERRY, P.A., BENNETT, C., SCHOLLER, I. & STEVENSON, I.H. Pharmacologic studies of vascular structure and function in hypertension, 444P
SILKE, B. *see* GUY, S.
SIMOOYA, O.O., MUTETWA, S., NEILL, P. & CHANIWANA, S.K. Artemether *vs* chloroquine in uncomplicated malaria, 447P
SITAR, D.S. *see* WONG, L.T.Y.
SKJELBO, E. & BRØSEN, K. Inhibitors of imipramine metabolism by human microsomes, 256
SLAGHIUS, G. *see* MATTIE, H.
SLEVIN, M. *see* OSBORNE, R.
SMALL, R.C. *see* FOSTER, R.W.
SMITH, B. *see* DENWORTHY, D.
SMITH, D.A. *see* GARDNER, I.B.
SMITH, D.A. *see* NEWLANDS, A.J.
SMITH, J.M. *see* CAMPBELL, M.
SMITH, J.M. *see* LEE, A.
SMITH, R.L. *see* ZHANG, A.Q.
SMYTH, D.D. *see* WONG, L.T.Y.
SOMOGYI, A.A. *see* MILNE, R.W.
SPENCER, D.A. *see* COOK, A.J.
SPIEGELHALTER, D.J. *see* BEST, N.G.
SPIERS, J.P. & JONES, D.L. Adrenergic stimulation in cardiomyopathic (CHF 146) and normal (CHF GS) Syrian hamsters: an electrophysiological study, 452P
SPIERS, J.P. *see* JONES, D.L.
SPIGELMAN, A. *see* NOTARIANNI, L.J.
SPINA, E. *see* PISANI, F.
STANNERS, A. *see* BRADBURY, H.
STEINHAUSLIN, F. *see* CHATTON, J.Y.
STEVEN, E.A. *see* WYNNE, H.A.
STEVENSON, I.H. *see* AL-LANQAWI, Y.
STEVENSON, I.H. *see* SHEPHERD, A.M.M.
STINSON, J. *see* CHAN, R.
STINSON, J., MCCORMACK, P.M.E., HEMERYCK, L. & FEELY, J. Implications for warfarin therapy: doctor and patient knowledge, 445P
STONE, R.A., BARNES, P.J. & FULLER, R.W. The low-chloride cough response is not inhibited by a single high dose of aspirin, 370
STORR, R.C. *see* HARRISON, A.C.
STRUTHERS, A.D. *see* MOTWANI, J.G.
STRUTHERS, A.D. The effect of ACE inhibitors and atrial natriuretic factor on the cardiorenal axis in man, 21
SUMMERBELL, J., WILLIAMS, F.M., HANKEY, C.R. & WYNNE, H.A. The influence of supplemented diet on blood esterases in the frail elderly, 159P
SUTCLIFFE, F. *see* RILEY, S.A.
SVEDBERG, L.-E. *see* UNGE, P.
SWEETLAND, J. *see* FOWLER, P.A.

TABAQCHALI, S. *see* GOROG, D.
TABAQCHALI, S. *see* SEERHA, R.
TAN, K.K.C. *see* BEST, N.G.
TASKER, T.C. *see* DENWORTHY, D.
TASSENEEYAKUL, W., VERONESE, M.E., BIRKETT, D.J., DOECKE, C.J., MCMANUS, M.E., SANSOM, L.N. & MINERS, J.O. Co-regulation of phenytoin and tolbutamide metabolism in humans, 494
TAVENDALE, R. *see* BRIDGES, A.B.
TEDESCHI, L. *see* FERRARA, S.D.
TEMPLETON, E. *see* PIRMOHAMED, M.
THAM, T.C.K. *see* GUY, S.
THOM, S. MCG., GOLDBERG, P., HUGHES, A.D. & SEVER, P.S. Peripheral pre-synaptic autoregulation by α_2-adreno-ceptors in man, 457P
THOMAS, D. *see* FOWLES, S.E.
THOMAS, M. *see* FOWLER, P.A.
THOMAS, S.H.L. Impedance cardiography using the Sramek-Bernstein method: accuracy and variability at rest and during exercise, 467
THOMAS, V.E., O'CONNELL, F., HARRISON, A.J. & FULLER, R.W. Ipratropium bromide delivered orally by metered dose inhaler does not decrease salivary flow in normal subjects, 266
THOMPSON, M. *see* ARNOLD, J.M.O.
THOMPSON, P. *see* OSBORNE, R.
THOMSON, D. *see* HE, G.-W.
TILL, P. *see* BAUER, K.G.
TINGLE, M.D. & PARK, B.K. The cell selective toxicity of paracetamol, prilocaine and lignocaine in a three compartment system *in vitro*, 185P
TOMLINSON, B. *see* CHAN, J.C.N.
TOMLINSON, P.W. *see* DENWORTHY, D.
TOMSON, T. *see* PISANI, F.
TONKIN, A.L. *see* MINERS, J.O.
TOUCHETTE, M.A., CHANDRASEKAR, P.H., MILAD, M.A. & EDWARDS, D.J. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man, 75
TRAVERS, A.F. *see* BRADBURY, H.
TREW, D. *see* OSBORNE, R.
TROTTER, T.N. A comparison of gastric emptying rate after cimetidine and ranitidine measured by applied potential tomography, 278
TROTTER, T.N. *see* MUSHAMBI, M.C.
TRULL, A.K. *see* BEST, N.G.
TSAO, Y. *see* NG, H.W.K.
TUCKER, G.T. & RAMSAY, L.E. Harvard to Vancouver—time for a change, 95
TUCKER, G.T. *see* BARHAM, H.M.
TUCKER, G.T. *see* CREWE, H.K.
TUCKER, G.T. *see* DANIELS, L.
TUCKER, G.T. *see* DHADYALLA, A.S.
TUCKER, G.T. *see* ELLIS, S.W.
TUCKER, G.T. *see* GARDNER, I.B.
TUCKER, G.T. *see* WHALLEY, P.M.
TURNBERG, L.A. *see* RILEY, S.A.
TURNER, P. *see* GOROG, D.
TURNER, P. *see* RAVIC, M.
TURNER, P. *see* SALEH, S.
TURNER, P. *see* SEERHA, R.

UNGE, P., SVEDBERG, L.-E., NORDGREN, A., BLOM, H., ANDERSSON, T., LAGERSTRÖM, P.-O. & IDSTRÖM, J.-P. A study of the interaction of omeprazole and warfarin in anticoagulated patients, 509
UPWARD, J. *see* ALLEN, A.

VADAS, E.B. *see* YOGENDRAN, L.
VAN DYK, M. *see* CROME, P.
VAN HECKEN, A.M., DEPRE, M., DE SCHEPPER, P.J., FOWLER, P.A., LACEY, L.F. & DURHAM, J.M. Lack of effect of flunarizine on the pharmacokinetics and pharmaco-dynamics of sumatriptan in healthy volunteers, 82
VAN PELT, F.N.A.M. *see* KENNA, J.G.
VAN STRIJEN, E. *see* MATTIE, H.
VENTRESCA, G.P. *see* MILLSON, D.S.
VERBOV, J.L. *see* COLEMAN, M.D.
VERCRUYSSE, I., SCHOORS, D.F., MASSART, D.L. & DUPONT, A.G. Influence of nicardipine on the pharmacokinetics of sustained release propranolol in healthy volunteers, 445P
VERNON, J.P. *see* HOSIE, J.
VERONESE, M.E. *see* TASSENEEYAKUL, W.
VONDERSCHER, J. *see* DREWE, J.

WAGEMANS, I., SCHOORS, D.F. & DUPONT, A.G. Captopril and losartan potentiate the natriuretic responses to fenoldopam, 463P
WALDEN, R.J. *see* CHAN, J.C.N.
WALKER, D. *see* GARDNER, I.B.
WALKER, D.K. & HUMPHREY, M.J. Demonstration of the hepatic uptake and redistribution of amlodipine using the rat isolated perfused liver, 150P
WALKER, R.J. *see* PRATT, M.C.
WALLER, D.G. *see* RENWICK, A.G.
WALLEY, T. *see* NG, H.W.K.
WALLWORK, J. *see* BEST, N.G.

WALSH, M.J. *see* SHEAHAN, R.G.
WARD, A. *see* KANE, P.J.
WARD, S. & BACK, D.J. Metabolism of the oral contraceptive steroid gestodene by human liver *in vitro*, 165P
WARRINGTON, S.J. *see* RAVIC, M.
WARRINGTON, S.J. *see* WRIGHT, D.M.
WATSON, P. *see* ELLIS, S.W.
WEBER, W. *see* BROCKMÖLLER, J.
WELBURY, R.R. *see* MEECHAN, J.G.
WELLER, C. *see* KIROLLOS, C.
WESLEY, R.C. *see* NYBERG, G.F.
WHALLEY. P.M., TUCKER, G.T. & REILLY, C.S. The effect of propofol on propranolol metabolism by rat and dog liver microsomes, 163P
WHATELEY, T.L. *see* ELEY, J.G.
WHEELDON, N.M., MCDEVITT, D.G. & LIPWORTH, B.J. Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects, 337
WHEELDON, N.M., PRINGLE, T.H. & LIPWORTH, B.J. Obstructive left ventricular hypertrophy: clinical and haemodynamic improvement using atenolol and verapamil, 456P
WHEELER, S.M. *see* HARRELL, A.W.
WHITE, N.J. Antimalarial pharmacokinetics and treatment regimens, 1
WHITEHEAD, A. *see* CHALMERS, D.
WIJAYAWARDHANA, P. *see* CROME, P.
WILKES, M.P. *see* KEY, B.J.
WILLIAMS, F.M. *see* MCCRACKEN, N.
WILLIAMS, F.M. *see* SUMMERBELL, J.
WILLIAMS, P.E.O. *see* MUIRHEAD, G.J.
WILLIAMS, P.E.O., MUIRHEAD, G.J., MADIGAN, M.J., MITCHELL, A.M. & SHAW, T. Disposition and bioavailability of the HIV-proteinase inhibitor, Ro 31-8959, after single doses in healthy volunteers, 155P
WOLF, C.R. *see* DANIELS, L.
WOLF, D. *see* FAIRLESS, A.J.
WONG, L.T.Y., SMYTH, D.D. & SITAR, D.S. Stereoselective inhibition of renal organic cation transport in human kidney, 438
WOOD, A.J. *see* ANTIA, I.J.
WOODS, F.R. *see* CREWE, H.K.
WOODS, H.F. *see* BARHAM, H.M.
WOODS, H.F. *see* ELLIS, S.W.
WOODWARD, A. *see* FOWLES, S.E.
WRIGHT, D.M., WARRINGTON, S.J. & DRUCKER, R.F. Comparison of the effects of morphine and the κ selective agonist U-62,066E in man, 183P
WYNNE, H.A. *see* SUMMERBELL, J.
WYNNE, H.A., STEVEN, E.A. & RAWLINS, M.D. Are systemic concentrations of NSAIDs relevant to acute upper gastrointestinal haemorrhage, 180P

YACOUB, M.H. *see* ALLEN, S.P.
YANG, C.-Q. *see* HE, G.-W.
YEE, K.F. *see* ALLEN, A.
YEO, W.W. *see* HIGGINS, K.S.
YEO, W.W. *see* LAKE, S.R.
YOGENDRAN, L., MCLAUGHLIN, K., VADAS, E.B., MARGOLSKEE, D.J., BECHARD, S., HSEIH, J.Y.-K., LIN, C., ROGERS, J.D., SCIBERRAS, D.G. & JAMES, I.M. Comparative bioavailability of different formulations of MK-679, an orally active LTD_4 receptor agonist, 169P
YOUNG, D. *see* PAXTON, J.W.

ZHANG, A.Q., MITCHELL, S.C., AYESHI, R. & SMITH, R.L. Urinary amines and neomycin treatment in man, 451P
ZOMORODI, K. & HOUSTON, J.B. Omeprazole inhibition of oxidative drug metabolism, 167P
ZOTTI, S. *see* FERRARA, S.D.

SUBJECT INDEX

This index was compiled from the keywords

(P = proceedings, S = supplement)

192C86, 344
α-adrenoceptor, 236
α-adrenoceptor antagonist, 179P
α_1-adrenoceptor antagonist, 176P
α_2-adrenoceptor antagonism, 521
α_2-adrenoceptor antagonists, 555
α_2-adrenoceptors, 448P, 457P
ACE activity, 151P
ACE gene, 151P
ACE inhibitor, 115, 176P
ACE inhibitors, 21
AG-EE 623 ZW, 173P
AH 21-132, 527
Absorption, 148P
Accuracy, 467
Acute myocardial infarction, 25S
Adenosine, 442P
Adrenaline, 156P
Adrenergic stimulation, 452P
Adverse drug reaction, 157P, 158P
Adverse drug reaction monitoring, 215
Adverse drug reaction reporting, 421
Advertisements, 158P
Age, 452P
Alacepril, 366
Albumin, 168P
Alcohol, 460P
Alcohol dependence, 231
Algorithmic methods, 157P
7-alkoquinoline, 415
Allopurinol, 449P
Amantidine, 438
Amlodipine, 150P
Anaesthesia, 442P
Analgesia, 130
Angina, 11S
Angiotensin I converting enzyme inhibitor, 224
Angiotensin II, 25, 443P, 457P
Angiotensin converting enzyme inhibitor, 366
Angiotensin converting enzyme inhibitors, 363
Animal models, 199, 302
Anti-infective drug prescribing, 458P, 459P
Antibiotics, 275, 310, 447P, 458P
Antibodies, 154
Anticholinergic, 328
Anticoagulants, 445P, 486
Anticoagulation, 509
Antiemetic, 144
Antihistamine, 326
Antimalarials, 1, 322
Antimuscarinics, 266
Antitumour agent, 174
Aortic blood velocity, 451P
Applied potential tomography, 180P, 278
Artemether, 447P
Aspirin, 182P, 370, 453P
Asthma, 122, 402
Atenolol, 32, 40, 337, 456P
Atrial natriuretic factor, 21, 102
Atriopeptidase inhibitor, 171P
Autoantibodies, 166P
Autonomic nervous system, 328
Azole resistance, 465P

β-adrenoceptor antagonist, 179P
β-adrenoceptor antagonists, 272P
BPPA, 122
BRL 42810, 164P
Benzodiazepines, 289
Bioavailability, 47, 155P, 169P
Bioequivalence, 309
Bioimpedance, 467
Blood cyclosporin concentration, 513
Blood dyscrasias, 377
Blood pressure, 115
Book review, 310
Bronchial provocation, 402
Bronchconstriction, 71
Bronchodilators, 527
Butylamino-phenoxy-propanol-acetate, 122
Bypass graft, 409

CYP2D6, 256
Calcium antagonist, 176P
Calcium antagonists, 199
Calcium channel, 199
Candida albicans, 465P
Candoxatril, 171P
Captopril, 25, 215, 463
Carbamazepine, 85
Carbamazepine-10,11-epoxide, 85
Cardiomyopathy, 452P
Cardiorenal axis, 21
Cardiovascular, 344
Cardiovascular reflexes, 207
Celiprolol, 179P, 337
Cerebral haemodynamics, 224
Cerebral ischaemia, 199
Cerebrospinal fluid, 79
Chloride, 370
Chloroquine, 447P
Cholecystokinin, 464P
Cigarette smoking, 415
Cimetidine, 244, 278
Ciprofloxacin, 169P
Citalopram, 262
Clinical pharmacology, 375
Clinical trials, 156P
Cloxacillin, 275
Clozapine, 168P
Co-regulation, 494
Co-trimoxazole, 551
Colorectal carcinoma, 153P
Competitive NMDA antagonists, 396
Compliance, 446
Congestive cardiac failure, 446P
Conjugation, 150P
Controlled release, 15S
Controlled trials, 352
Coronary angioplasty, 444P
Coronary circulation, 454P, 541
Coronary surgery, 236
Cortisol, 163P
Cough reflex, 182P
Cough response, 370
Counterregulation, 547
Cutaneous reactions, 377
Cyclosporin, 60
Cytochrome P450, 153, 415, 494
Cytochrome P450 2C, 152P
Cytochrome P450 3A4, 164P
Cytochrome P450 6, 262
Cytochrome P4501A2, 153P
Cytoprotection, 486

DP-receptors, 344
Dapsone, 244
Debrisoquine 4-hydroxylase, 152P
Debrisoquine hydroxylator status, 164P
Diabetes, 442P
Diet, 159P
Diethylcarbamazine, 281
Digoxin, 451P
Dobutamine, 179P, 451P
Doctor knowledge, 445P
Dopamine agonism, 269
Doppler ultrasound, 451P
Dose titration, 115
Drug absorption, 32, 40
Drug interaction, 85, 551
Drug metabolism, 359, 494
Drug side effects, 266
Drug treatment, 144
Dyspepsia, 464P

EDRF, 29S
EEG, 65
ELISA detection system, 464P
Elderly, 154, 159P, 178P, 450P
Electrical bioimpedance cardiography, 177P
Enalapril, 456P
Enantiomers, 139, 154P, 172P
Endogenous nitrates, 29S
Endothelium, 409
Endothelium derived relaxing factor, 29S, 37S
Enoxacin, 169P
Enzyme inhibition, 322
Epidural, 431
Erythrocyte membrane, 427
Erythropoietin, 363
Essential hypertension, 366
Esterases, 159P, 160P
Ethanol, 316
Ethyl methyl sulphide, 160P
Ethylmorphine, 250
European challenge, 375
Exercise, 177P
Exercise test, 366
Exogenous nitrates, 29S

Expert judgements, 157P
Extrapolation, 316

Famciclovir, 164P, 171P, 449S, 450P
Familial adenomatous polyposis, 153P, 164P
Felodipine, 454P
Fenoldopam, 463P
Fibrinogen, 455P
Fish-odour syndrome, 451P
Flare response, 181P
Flavin-containing monooxygenase, 160P
Flosequinan, 177P, 207
Fluconazole, 75
Fluidity, 427
Flunarizine, 82
5-fluoroamodiaquine, 148P
Fluoxetine, 262
Fluvoxamine, 262
Focal and forebrain ischaemia, 199
Focal cerebral ischaemia, 302
Frusemide, 25, 32, 40, 47, 71
Functional bowel disorder, 448P

γ-L-glutamyl-5-hydroxy-L-tryptophan, 149P
γ-aminobutryic acid, 231
GR43175, 454P
Gastric emptying, 32, 180P, 278, 332
Gastrointestinal haemorrhage, 180P
General practice, 183P
General practitioner, 184P
Genetic polymorphism, 256
Gestodene, 165P
Ginkgo biloba, 352
Glibenclamide, 442P
Glucagon, 547
Glucose, 40, 547
Glucose appearance rate, 547
Glucuronidation, 434
Glucuronide metabolites, 53
Glutamate receptor, 106
Glyceryl trinitrate, 236
Glycine, 150P
Granisetron, 65, 175P

HIV proteinase inhibitor, 155P, 166P, 170P
Haematological effects, 460P
Haemodialysis, 499
Haemodynamic tolerance, 15S
Haemodynamics, 177P, 541
Halothane, 154P, 166P
Head injury, 396
Healthy volunteers, 207, 224, 344
Heart failure, 25S
Heart lung transplantation, 513
Hepatitis, 154P, 166P
Hepatitis, autoimmune chronic active, 464P
Hepatotoxicity, 377
High performance liquid chromatography, 447P
Histamine, 322, 402
5-HT_1 receptor, 541
5-HT_1 receptor agonist, 454P
5-HT_3, 65
5-HT_3 receptor antagonist, 175P
Human liver, 415
Human placenta, 139, 415
Human psychomotor performance, 289
Hydrochlorothiazide, 32, 40
5-hydroxytryptamine, 464P
Hyoscine butylbromide, 328
Hypercalcaemia, 11
Hypercholesterolaemia, 427
Hypersensitivity, 377
Hypertension, 215, 444P
Hypoglycaemia, 547
Hypoglycaemic drug, 173P

Iatrogenic disease, 183P
Idazoxan, 457P
Idiosyncratic drug reactions, 377
Imipramine, 256
Impedance cardiography, 88
Improved use, 281
Indocyanine green, 162P
Indomethacin, 456P
Infants, 434
Infusion, 115
Inhalation, 311
Inhaled medications, 309
Inhibition, 244
Insulin release, 521
Interaction, 82, 171P, 177P, 449P, 509
Internal mammary artery, 236
Intraocular pressure, 122, 269
Ipratropium bromide, 71, 266
Ischaemic brain damage, 106, 396
Ischaemic heart disease, 19S, 272
Isoflurane, 442P
Isosorbide-5-mononitrate, 15S

κ-selective agonist, 183P
Kalaemotropic effect, 156P
Ketoconazole, 75
Kidney disease, 462P

L-659,066, 521
Lactulose, 40
Left ventricular hypertrophy, 456P
Leukotriene D_4 receptor antagonist, 169P
Leukotrienes, 155P, 409
Levcromakalim, 449P
Lipid composition, 427
Lipoprotein(a), 462P
Lisinopril, 456P
Lithium, 535
Local anaesthetic, 156P
Logistic regression, 513
Losartan, 463P
Lovastatin, 427
Lower body negative pressure, 207
Lung function, 122
Lymphocytes, 535

M&B22948, 181P
M-mode echocardiography, 88
MK-679, 169P
Malaria, 447P
Man, 244
Manic-depressive psychosis, 535
Mannitol, 40
Medifoxamine, 269
Menopause, 462P
Menstrual cycle, 250
Mental functioning, 352
Mephenytoin, 256
Metabolic clearance, 359
Metabolic ratio, 359
Metabolism, 75
Metformin, 442P
Methacholine, 527
Method comparisons, 88
Metoclopramide, 32
Metoprolol, 161P
Microemulsion, 60
Microencapsulation, 186P
Microfilaricide, 281
Microsomes, 250, 256
Mitomycin-c, 186P
Mizolastine, 328
Moclobemide, 162P
Morphine, 53, 130, 183P, 431, 434
Morphine-3-glucuronide, 431
Morphine-6-glucuronide, 130, 431
3-morpholino-sydnonimine, 181P
Mortality, 25S
Myocardial infarction, 455P
Myocardial ischaemia, 29S, 444P

N-(2-(dimethylamino)ethyl)acridine-4-carboxamide, 174P
N-acetyl-glucosaminidase, 442P
N-hydroxylation, 244
N-methyl transferase, 322
N-methyl-D-aspartate, 106
Na^+/Ca^+ ion-channel modulation, 199
Na^+/K^+ pumps, 535
Natriuresis, 25
Natriuretic response, 463P
Neomycin, 451P
Neonates, 434
Neurohumoral activation, 11S
Nicardipine, 445P
Nifedipine, 178P, 332, 454P
Nitrate tolerance, 19S
Nitrates, 5S, 19S, 25S, 96, 444P
Nitric oxide, 11S, 37S
Nitric oxide donors, 181P
Nitro-vasodilators, 453P
Non-contact tonometer, 269
Non-linear binding models, 115
Non-steroidal anti-inflammatory drugs, 152P, 180P, 446P
Normal human subjects, 527

Obituary, 373
Oestrogen receptor, 462P
Omeprazole, 167P, 509
Onchocerciasis, 281
Ondansetron, 144, 181P
Ophthalmic β-adrenoceptors, 122
Oral absorption, 60
Oral contraceptive, 165P
Organic acids, 175P
Organic nitrates, 5S
Oro-caecal transit, 32
Osmotic effects, 40
Oxidative drug metabolism, 167P

Paracetamol, 79, 359
Parkinsonism, 185P
Paroxetine, 262
Partial agonist, 179P
Partial agonist activity, 337

Patient knowledge, 445P
Patients, 509
Patients' attitudes, 156P
Penciclovir, 450P
Perinodoprilat, 115
Pharmacodynamic modelling, 499
Pharmacodynamics, 5S, 15S, 47, 82
Pharmacokinetic probe, 160P
Pharmacokinetics, 1, 5S, 15S, 47, 79, 82, 115, 130, 162P, 166P, 169P, 170P, 173P, 175P, 178P, 231, 236, 316, 332, 445P, 446P, 449P, 450P, 499, 551
Phase 1 units, 459P
Phenytoin, 75, 168P, 494
Plasma concentrations, 53
Platelet aggregation, 344
Polymorphism, 151P, 164P
Post-marketing surveillance, 215
Posture, 332
Potency, 5S
Pre-eclampsia, 181P
Pregnancy, 250
Prescribing, 184P
Prescribing habits, 461P
Prilocaine, 185P
Prodrug, 79, 149P, 171P
Progesterone, 250
Propofol, 163P
Propranolol, 163P, 445P
Prostaglandin D_2, 402
Protein binding, 175P
Psychometric performance, 65
Pulmonary circulation, 454P
Pupil size, 328

Quinidine, 161P, 438
Quinine, 161P, 438

Ramipril, 224
Ranitidine, 278
Reactions, 281
Recognition of prescribed drugs, 460P
Recombinant erythropoietin, 499
Regional blood flows, 207
Rejection, 513
Renal anaemia, 499
Renal clearance, 53, 359
Renal function, 53
Renal secretion, 175P
Renin-angiotensin system, 363
Renin-angiotensin-aldosterone system, 366
Respiratory tract infection, 447P
Risk, 144
Ro 31-8959, 155P, 166P, 170P

Salbutamol, 311
Salicylate concentrations, 182P
Salicylic acid, 32, 40
Salivary flow, 266
Salivary secretion, 555
Salivation, 328
Salmeterol, 177P
Selectivity, 179P
Sertaline, 262
Skin, 148P
Sodium metabisulphite, 71
Sodium nitroprusside, 181, 442P
Sodium valproate, 173P
Sparteine, 256
Species differences, 163P
Steroids, 486
Streptokinase, 455P
Stroke, 302, 477, 486
Stroke volume, 467
Subdural haematoma, 396
Sucrose, 527
Sulphydryl groups, 11S
Sumatriptan, 82, 454P, 541
Synovial fluid, 275
Systolic time intervals, 467

Tachyphylaxis, 443P
Tamoxifen, 153P
Temazepam, 289
Testosterone, 75
Theophylline, 169P, 171P
Thrombolysis, 455P
Thrombolytics, 455P
Thromboxane receptor antagonist, 402
Tissue ACE, 115
Tissue distribution, 322
Tolbutamide, 494
Tolerability, 166P, 454P
Tolerance, 11S, 96
Toxicity, 185P
Transcranial Doppler, 224
Transport, 139
Tricyclic antidepressants, 555
Trimethoprim, 551

U-62,066E, 183P
Ulcerative colitis, 189
Urinary amines, 451P
Urinary excretion, 311

Valnoctamide, 85
Variability, 32, 467
Vascular reactivity, 409
Vasodilator drugs, 461P
Verapamil, 456P
Vigabatrin, 139
Viral bronchiolitis, 155P
Volunteer payments, 459P

Warfarin, 154P, 172P, 445P, 509
White blood cell aggregation, 272

Xamoterol, 177P

Yohimbine, 555
Young, 155P, 178P

Zidovudine, 165P, 446P, 551